- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£830GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21269EUR$22,000USD£18,269GBP
- Drug Pipelines
- July 2018
- 503 Pages
Global
From €21269EUR$22,000USD£18,269GBP
- Report
- May 2018
- 61 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- May 2023
- 102 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- February 2024
- 182 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- January 2022
- 220 Pages
Global
From €5963EUR$6,168USD£5,122GBP
Enbrel is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein composed of the extracellular ligand-binding portion of the human 75 kDa tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Enbrel works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation.
Enbrel is a widely used drug in the immune disorder drug market. It is approved for use in adults and children over the age of four. It is administered as a subcutaneous injection and is available in both prefilled syringes and autoinjectors.
The Enbrel market is highly competitive, with several companies offering similar products. These include Amgen, Pfizer, AbbVie, Janssen, and UCB. Show Less Read more